Literature DB >> 19289058

Atomistic insights into regulatory mechanisms of the HER2 tyrosine kinase domain: a molecular dynamics study.

Shannon E Telesco1, Ravi Radhakrishnan.   

Abstract

HER2 (ErbB2/Neu) is a receptor tyrosine kinase belonging to the epidermal growth factor receptor (EGFR)/ErbB family and is overexpressed in 20-30% of human breast cancers. Although several crystal structures of ErbB kinases have been solved, the precise mechanism of HER2 activation remains unknown, and it has been suggested that HER2 is unique in its requirement for phosphorylation of Y877, a key tyrosine residue located in the activation loop. To elucidate mechanistic details of kinase domain regulation, we performed molecular dynamics simulations of a homology-modeled HER2 kinase structure in active and inactive conformations. Principal component analysis of the atomistic fluctuations reveals a tight coupling between the activation loop and catalytic loop that may contribute to alignment of residues required for catalysis in the active kinase. The free energy perturbation method is also employed to predict a role for phosphorylated Y877 in stabilizing the kinase conformations. Finally, simulation results are presented for a HER2/EGFR heterodimer and reveal that the dimeric interface induces a rearrangement of the alphaC helix toward the active conformation. Elucidation of the molecular regulatory mechanisms in HER2 will help establish structure-function relationships in the wild-type kinase, as well as predict mutations with a propensity for constitutive activation in HER2-mediated cancers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19289058      PMCID: PMC2907720          DOI: 10.1016/j.bpj.2008.12.3912

Source DB:  PubMed          Journal:  Biophys J        ISSN: 0006-3495            Impact factor:   4.033


  51 in total

Review 1.  Cell signaling by receptor tyrosine kinases.

Authors:  J Schlessinger
Journal:  Cell       Date:  2000-10-13       Impact factor: 41.582

Review 2.  EGF-ERBB signalling: towards the systems level.

Authors:  Ami Citri; Yosef Yarden
Journal:  Nat Rev Mol Cell Biol       Date:  2006-07       Impact factor: 94.444

3.  Single mutation induced H3N2 hemagglutinin antibody neutralization: a free energy perturbation study.

Authors:  Ruhong Zhou; Payel Das; Ajay K Royyuru
Journal:  J Phys Chem B       Date:  2008-12-11       Impact factor: 2.991

4.  c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function.

Authors:  R C Ishizawar; T Miyake; S J Parsons
Journal:  Oncogene       Date:  2006-12-18       Impact factor: 9.867

5.  The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand.

Authors:  Samuel Bouyain; Patti A Longo; Shiqing Li; Kathryn M Ferguson; Daniel J Leahy
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-03       Impact factor: 11.205

6.  Transactivating agonists of the EGF receptor require Tyr 845 phosphorylation for induction of DNA synthesis.

Authors:  Julie L Boerner; Jacqueline S Biscardi; Corinne M Silva; Sarah J Parsons
Journal:  Mol Carcinog       Date:  2005-12       Impact factor: 4.784

7.  Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation.

Authors:  Ami Citri; Judith Gan; Yaron Mosesson; Gyorgi Vereb; Janos Szollosi; Yosef Yarden
Journal:  EMBO Rep       Date:  2004-12       Impact factor: 8.807

8.  Mechanism of biological synergy between cellular Src and epidermal growth factor receptor.

Authors:  D A Tice; J S Biscardi; A L Nickles; S J Parsons
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

9.  Molecular systems biology of ErbB1 signaling: bridging the gap through multiscale modeling and high-performance computing.

Authors:  Andrew J Shih; Jeremy Purvis; Ravi Radhakrishnan
Journal:  Mol Biosyst       Date:  2008-09-12

10.  Absence of autophosphorylation site Y882 in the p185neu oncogene product correlates with a reduction of transforming potential.

Authors:  H T Zhang; D M O'Rourke; H Zhao; R Murali; Y Mikami; J G Davis; M I Greene; X Qian
Journal:  Oncogene       Date:  1998-06-04       Impact factor: 9.867

View more
  21 in total

1.  Molecular dynamics analysis of conserved hydrophobic and hydrophilic bond-interaction networks in ErbB family kinases.

Authors:  Andrew J Shih; Shannon E Telesco; Sung-Hee Choi; Mark A Lemmon; Ravi Radhakrishnan
Journal:  Biochem J       Date:  2011-06-01       Impact factor: 3.857

2.  Medicinal chemistry for 2020.

Authors:  Seetharama D Satyanarayanajois; Ronald A Hill
Journal:  Future Med Chem       Date:  2011-10       Impact factor: 3.808

Review 3.  Structural systems biology and multiscale signaling models.

Authors:  Shannon E Telesco; Ravi Radhakrishnan
Journal:  Ann Biomed Eng       Date:  2012-04-27       Impact factor: 3.934

4.  Carboxyl-group footprinting maps the dimerization interface and phosphorylation-induced conformational changes of a membrane-associated tyrosine kinase.

Authors:  Hao Zhang; Wei Shen; Don Rempel; John Monsey; Ilan Vidavsky; Michael L Gross; Ron Bose
Journal:  Mol Cell Proteomics       Date:  2011-03-21       Impact factor: 5.911

5.  Exploring the dynamics and interaction of a full ErbB2 receptor and Trastuzumab-Fab antibody in a lipid bilayer model using Martini coarse-grained force field.

Authors:  Juan Felipe Franco-Gonzalez; Javier Ramos; Victor L Cruz; Javier Martinez-Salazar
Journal:  J Comput Aided Mol Des       Date:  2014-08-17       Impact factor: 3.686

Review 6.  The role of HER2 in cancer therapy and targeted drug delivery.

Authors:  Wanyi Tai; Rubi Mahato; Kun Cheng
Journal:  J Control Release       Date:  2010-04-10       Impact factor: 9.776

7.  Investigating Molecular Mechanisms of Activation and Mutation of the HER2 Receptor Tyrosine Kinase through Computational Modeling and Simulation.

Authors:  Shannon E Telesco; Andrew Shih; Yingting Liu; Ravi Radhakrishnan
Journal:  Cancer Res J       Date:  2011

8.  Conformational flexibility of the ErbB2 ectodomain and trastuzumab antibody complex as revealed by molecular dynamics and principal component analysis.

Authors:  Juan Felipe Franco-Gonzalez; Victor L Cruz; Javier Ramos; Javier Martínez-Salazar
Journal:  J Mol Model       Date:  2012-11-17       Impact factor: 1.810

9.  Prognostic impact of phosphorylated HER-2 in HER-2+ primary breast cancer.

Authors:  Naoki Hayashi; Takayuki Iwamoto; Ana M Gonzalez-Angulo; Jaime Ferrer-Lozano; Ana Lluch; Naoki Niikura; Chandra Bartholomeusz; Seigo Nakamura; Gabriel N Hortobagyi; Naoto T Ueno
Journal:  Oncologist       Date:  2011-06-28

Review 10.  Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapies.

Authors:  Michael Luis; Ana Tavares; Liliana S Carvalho; Lúcio Lara-Santos; António Araújo; Ramon Andrade de Mello
Journal:  World J Gastroenterol       Date:  2013-10-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.